19 May 2013
Keywords: bioprogress, fails, break, even, uk, provider, delivery
Article | 15 March 2004
The UK's BioProgress, a provider of delivery mechanisms for the pharmaceutical oral dosage markets, has reported a pretax net loss ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 March 2004
17 May 2013
© 2013 thepharmaletter.com